Bayer's Classon steps up to strategy role
This article was originally published in Clinica
Executive Summary
Bayer's diagnostics division head Rolf Classon has been appointed to the new post of group healthcare strategy and business development head. The new position is part of the group's restructuring, which will see the creation of a new holding company and four operational units, including healthcare (see Clinica No 1000, p 21).
You may also be interested in...
Waters Muddied As Bharat Readies COVID-19 Vaccine For '21 Launch
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
PMDA Eyes More Japan-First Approvals In Access Push
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
QUOTED. 27 November 2020. Agam Sharda.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: